Cancer Letters
Volume 299, Issue 1 , Pages 45-53 , 18 December 2010

Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells

  • Qinghang Meng

      Affiliations

    • Department of Environmental Health, University of Cincinnati, College of Medicine, Cincinnati, OH 45267, United States
    • ,
  • Zhimin Peng

      Affiliations

    • Department of Environmental Health, University of Cincinnati, College of Medicine, Cincinnati, OH 45267, United States
    • Present address: Radiation Oncology Research Laboratory, University of Maryland, Bressler Research Building, 7-017, 655 West Baltimore St., Baltimore, MD 21201, United States.
    • ,
  • Liang Chen

      Affiliations

    • Department of Environmental Health, University of Cincinnati, College of Medicine, Cincinnati, OH 45267, United States
    • ,
  • Jutong Si

      Affiliations

    • Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, United States
    • ,
  • Zhongyun Dong

      Affiliations

    • Department of Internal Medicine, University of Cincinnati, College of Medicine, Cincinnati, OH 45267, United States
    • ,
  • Ying Xia

      Affiliations

    • Department of Environmental Health, University of Cincinnati, College of Medicine, Cincinnati, OH 45267, United States
    • Corresponding Author InformationCorresponding author. Address: Department of Environmental Health, College of Medicine, University of Cincinnati, 123 East Shields Street, Cincinnati, OH 45267-0056, United States. Tel.: +1 513 558 0371; fax: +1 513 558 4397.

Received 26 February 2010 ,Revised 6 August 2010 ,Accepted 9 August 2010.

References 

  1. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18:6853–6866
  2. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–466
  3. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, et al. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell. 2004;119:529–542
  4. Chen F, Castranova V, Li Z, Karin M, Shi X. Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic. Cancer Res. 2003;63:7689–7693
  5. Peng Z, Peng L, Fan Y, Zandi E, Shertzer HG, Xia Y. A critical role for IkappaB kinase beta in metallothionein-1 expression and protection against arsenic toxicity. J. Biol. Chem. 2007;282:21487–21496
  6. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death – a new approach to cancer therapy. J. Clin. Invest. 2005;115:2625–2632
  7. Peng Z, Geh E, Chen L, Meng Q, Fan Y, Sartor M, et al. Inhibitor of {kappa}B kinase {beta} regulates redox homeostasis by controlling the constitutive levels of glutathione. Mol. Pharmacol. 2010;77:784–792
  8. Meister A, Anderson ME. Glutathione. Annu. Rev. Biochem. 1983;52:711–760
  9. Sierra-Rivera E, Meredith MJ, Summar ML, Smith MD, Voorhees GJ, Stoffel CM, et al. Genes regulating glutathione concentrations in X-ray-transformed rat embryo fibroblasts: changes in gamma-glutamylcysteine synthetase and gamma-glutamyltranspeptidase expression. Carcinogenesis. 1994;15:1301–1307
  10. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301–2307
  11. Barbarroja N, Ristides-Torres L, Hernandez V, Martin C, Dorado G, Torres A, et al. Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. Leukemia Lymphoma. 2007;48:1187–1199
  12. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia. 2004;18:103–112
  13. Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, et al. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum. Pathol. 2004;35:246–253
  14. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, et al. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate. 2002;52:183–200
  15. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 1999;18:7389–7394
  16. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005;5:749–759
  17. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst. 1992;84:951–957
  18. Collins SJ, Robertson KA, Mueller L. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol. Cell Biol. 1990;10:2154–2163
  19. Tojima Y, Fujimoto A, Delhase M, Chen Y, Hatakeyama S, Nakayama K, et al. NAK is an IkappaB kinase-activating kinase. Nature. 2000;404:778–782
  20. Yang H, Wang J, Ou X, Huang ZZ, Lu SC. Cloning and analysis of the rat glutamate–cysteine ligase modifier subunit promoter. Biochem. Biophys. Res. Commun. 2001;285:476–482
  21. Yang H, Wang J, Huang ZZ, Ou X, Lu SC. Cloning and characterization of the 5′-flanking region of the rat glutamate–cysteine ligase catalytic subunit. Biochem. J. 2001;357:447–455
  22. Senft AP, Dalton TP, Shertzer HG. Determining glutathione and glutathione disulfide using the fluorescence probe o-phthalaldehyde. Anal. Biochem. 2000;280:80–86
  23. Dalton TP, Chen Y, Schneider SN, Nebert DW, Shertzer HG. Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radical Biol. Med. 2004;37:1511–1526
  24. Melisi D, Chiao PJ. NF-kappa B as a target for cancer therapy. Expert. Opin. Ther. Targets. 2007;11:133–144
  25. Savickiene J, Treigyte G, Pivoriunas A, Navakauskiene R, Magnusson KE. Sp1 and NF-kappaB transcription factor activity in the regulation of the p21 and FasL promoters during promyelocytic leukemia cell monocytic differentiation and its associated apoptosis. Ann. NY Acad. Sci. 2004;1030:569–577
  26. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood. 2005;106:3917–3925
  27. Assef Y, Rubio F, Colo G, del MS, Costas MA, Kotsias BA. Imatinib resistance in multidrug-resistant K562 human leukemic cells. Leukemia Res. 2009;33:710–716
  28. Moon DO, Kim MO, Kang SH, Choi YH, Kim GY. Sulforaphane suppresses TNF-alpha-mediated activation of NF-kappaB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. Cancer Lett. 2009;274:132–142
  29. Zhou GB, Li G, Chen SJ, Chen Z. From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. Acta Pharmacol. Sin. 2007;28:1434–1449
  30. Wang ZY. Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis. Hematology. Am. Soc. Hematol. Educ. Program. 2003;45:1–13
  31. Soignet SL. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist. 2001;2(6 Suppl.):11–16
  32. Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem. Biol. Interact. 1998;111–112:1–14
  33. Aggarwal BB, Shishodia S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. NY Acad. Sci. 2004;1030:434–441
  34. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, et al. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J. Cell Sci. 2002;115:141–151
  35. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death. Differ. 2006;13:738–747
  36. Davison K, Mann KK, Miller WH. Arsenic trioxide: mechanisms of action. Semin. Hematol. 2002;39:3–7
  37. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999;94:2102–2111
  38. Miyajima A, Nakashima J, Yoshioka K, Tachibana M, Tazaki H, Murai M. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br. J. Cancer. 1997;76:206–210
  39. Ravi R, Bedi A. NF-kappaB in cancer – a friend turned foe. Drug Resist. Update. 2004;7:53–67
  40. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000;60:5334–5339
  41. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell Biol. 1999;19:5785–5799
  42. Bourguignon LY, Xia W, Wong G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J. Biol. Chem. 2009;284:2657–2671

PII: S0304-3835(10)00383-6

doi: 10.1016/j.canlet.2010.08.002

Cancer Letters
Volume 299, Issue 1 , Pages 45-53 , 18 December 2010

Article Tools

* Image Usage & Resolution